Canaccord Genuity analyst John Newman maintained a Buy rating on BioNTech SE (BNTX – Research Report) yesterday and set a price target of $171.44.
John Newman has given his Buy rating due to a combination of factors that highlight BioNTech’s promising oncology pipeline and its potential to drive long-term value. The company is expected to have a data-rich year with significant updates in its oncology trials, particularly for BNT327 in Small Cell Lung Cancer and the iNeST cancer vaccine in adjuvant melanoma. These developments are anticipated to overshadow the revenues from COVID-19 vaccines, which are projected to meet the company’s guidance.
Furthermore, BioNTech’s ongoing trials in various cancer types, such as Triple Negative Breast Cancer and HER2+ endometrial cancer, are expected to yield positive results, reinforcing the company’s strategic focus on oncology. The anticipated BLA submission for BNT323 and the potential approval in 2026 further strengthen the investment case. These factors, combined with a catalyst-heavy 2025, support the Buy rating and the price target of $171.
Newman covers the Healthcare sector, focusing on stocks such as Delcath Systems, Regeneron, and Merus. According to TipRanks, Newman has an average return of -3.9% and a 33.74% success rate on recommended stocks.
In another report released today, BMO Capital also maintained a Buy rating on the stock with a $143.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com